Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $740.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target increased by Citigroup from $700.00 to $740.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research report on Tuesday, July 7th. Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Finally, JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $797.75.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $768.58 on Monday. The business has a 50-day moving average of $650.88 and a 200-day moving average of $711.54. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market capitalization of $81.25 billion, a price-to-earnings ratio of 19.00, a price-to-earnings-growth ratio of 1.34 and a beta of 0.22. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $12.81 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals will post 43.11 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. WPG Advisers LLC raised its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the period. SHP Wealth Management acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $26,000. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $26,000. Titan Wealth CI Ltd bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $29,000. Finally, Kemnay Advisory Services Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts and quantitative models point to improving earnings-estimate revisions, suggesting potential near-term upside for REGN. Regeneron is also being highlighted as a relatively attractive value stock within the biomedical and genetics sector. Surging Earnings Estimates Signal Upside for Regeneron Stock
• Positive Sentiment: Guggenheim raised its price target for Regeneron to $1,030, a notably bullish view that reflects confidence in the company’s earnings power and long-term pipeline. Citigroup also adjusted its target to $740. Guggenheim Increases Regeneron Price Target
• Neutral Sentiment: Articles comparing REGN with Incyte (INCY) frame the decision as a value-investing choice rather than announcing a new company-specific development. Regeneron’s valuation remains supported by strong profitability and its previously reported quarterly earnings and revenue beat. REGN or INCY: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Multiple law firms announced or promoted a securities class action alleging that Regeneron and certain executives misled investors about the prospects and protocol of the Phase 3 Fianlimab-Libtayo melanoma trial. The trial’s failure reportedly contributed to a sharp prior selloff and an approximately $11 billion market-capitalization loss. Investors in the August 1, 2025–May 15, 2026 class period face a September 14, 2026 lead-plaintiff deadline. These announcements largely repeat the same allegations, but they reinforce litigation and reputational overhang. Regeneron Clinical Trials Lead to Securities Fraud Class Action

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.